Review of Clinical Trials for Mitochondrial Disorders: 1997-2012

Neurotherapeutics

Volumn 10, Issue 2, 2013, Pages 307-319

  Kerr, Douglas S ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

arginine; citrulline; creatine; crossover design; dichloroacetate; EPI 743; exercise; idebenone; Placebo controlled; primary outcomes; lipoate

Indexed keywords

ALPHA TOCOTRIENOL QUINONE; ARGININE; CITRULLINE; CREATINE; DICHLOROACETIC ACID; IDEBENONE; LIQNOL; THIOCTIC ACID; UBIDECARENONE; UBIQUINONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXERCISE; HUMAN; LACTIC ACIDOSIS; LEBER HEREDITARY OPTIC NEUROPATHY; MITOCHONDRIAL ENCEPHALOPATHY; PRIORITY JOURNAL; REVIEW;

EID: 84876167339     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0176-7     Document Type: Review

References (54)

1. Horvath R, Gorman G, Chinnery PF. How can we treat mitochondrial encephalomyopathies? Approaches to therapy. Neurotherapeutics 2008; 5: 558-568.
2. DiMauro S, Rustin P. A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases. Biochim Biophys Acta 2009; 1792: 1159-1167.
3. Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010; 99: 246-55.
4. Stacpoole PW. Why are there no proven therapies for genetic mitochondrial diseases? Mitochondrion 2011; 11: 679-685.
5. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; 4: CD004426.
6. Stacpoole PW, Barnes CL, Hurbanis MD, Cannon SL, Kerr DS. Treatment of congenital lactic acidosis with dichloroacetate: A review. Arch Dis Child 1997; 77: 535-541.
7. Barshop BA, Naviaux RK, McGowan KA, Levine F, Nyhan WL, Loupis-Geller A, et al. Chronic treatment of mitochondrial disease patients with dichloroacetate. Mol Genet Metab 2004; 83: 138-149.
8. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006; 117: 1519-531.
9. Stacpoole PW. The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither? Environ Health Perspect 2011; 119: 155-158.
10. Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006; 66: 324-330.
11. Kaufmann P, Pascual JM, Anziska Y, Gooch CL, Engelstad K, Jhung S, et al. Nerve conduction abnormalities in patients with MELAS and the A3243G mutation. Arch Neurol 2006; 63: 746-748.
12. Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005; 64: 710-712.
13. Koga Y, Akita Y, Junko N, Yatsuga S, Povalko N, Fukiyama R, et al. Endothelial dysfunction in MELAS improved by L-arginine supplementation. Neurology 2006; 66: 1766-1769.
14. Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Katayama K, et al. MELAS and L-arginine therapy. Mitochondrion 2007; 7: 133-139.
15. Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci 2010; 1201: 104-110.
16. Koga Y, Abe T, Taniwaki T, Nataliya P. MELAS and L-arginine therapy - therapeutic timing and long term effects. Mitochondrion 2012; 12; 551.
17. Coman D, Yaplito-Lee J, Boneh A. New indications and controversies in arginine therapy. Clin Nutr 2008; 27: 489-496.
18. Tein I. L-Arginine therapy on endothelium-dependent vasodilation & mitochondrial metabolism in MELAS syndrome. ClinicalTrials. gov: NCT01603446. 2012.
19. El-Hattab AW, Hsu JW, Emrick LT, Wong LJ, Craigen WJ, Jahoor F, et al. Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. Mol Genet Metab 2012; 105: 607-614.
20. El-Hattab AW, Emrick LT, Craigen WJ, Scaglia F. Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders. Mol Genet Metab 2012; 107: 247-252.
21. Quinzii CM, Lopez LC, Naini A, DiMauro S, Hirano M. Human CoQ10 deficiencies. Biofactors 2008; 32: 113-118.
22. Hirano M, Garone C, Quinzii CM. CoQ10 deficiencies and MNGIE: two treatable mitochondrial disorders. Biochim Biophys Acta 2012; 1820: 625-631.
23. Shults CW, Haas R. Clinical trials of coenzyme Q10 in neurological disorders. Biofactors 2005; 25: 117-126.
24. Eleff S, Kennaway NG, Buist NR, Darley-Usmar VM, Capaldi RA, Bank WJ, et al. 31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc Natl Acad Sci U S A 1984; 81: 3529-3533.
25. Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010; 42: 739-748.
26. Stacpoole PW, deGrauw TJ, Feigenbaum AS, Hoppel C, Kerr DS, McCandless SE, et al. Design and implementation of the first randomized controlled trial of coenzyme Q10 in children with primary mitochondrial diseases. Mitochondrion 2012; 12: 623-629.
27. Shults CW, Flint BM, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 2004; 188: 491-494.
28. Miles MV, Patterson BJ, Schapiro MB, Hickey FJ, Chalfonte-Evans M, Horn PS, et al. Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial. Pediatr Neurol 2006; 35: 30-37.
29. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007; 68: 20-28.
30. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 2007; 64: 938-944.
31. Beal MF, Oakes D, Shoulson I. Effects of coenzme Q10 (CoQ) in Parkinson disease; ClinicalTrials. gov: NCT007407140. 2009.
32. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007; 6: 878-886.
33. Perlman S, Lynch D. Study of the efficacy, safety, and tolerability of idebenone in the treatment of Friedreich's ataxia; ClinicalTrials. gov: NCT00537680. 2009.
34. Kaufmann P, Hirano M. Study of idebenone in the treatment of mitochondrial encephalopathy lactic acidosis & stroke-like episodes (MELAS); ClinicalTrials. gov, NCT00887562. 2009.
35. Meier T, Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol 2009; 256(Suppl. 1): 25-30.
36. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol 2010; 67: 941-947.
37. Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol 2012; 259: 284-291.
38. Hirano M. Study of idebenone in the treatment of mitochondrial encephalopathy lactic acidosis & stroke-like episodes (MELAS); clinicaltrials. gov, NCT00887562. 2012.
39. Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011; 134: 2677-2686.
40. Santhera Pharmaceuticals. Study with idebenone in patients with chronic vision loss due to Leber's hereditary optic neuropathy (LHON); ClinicalTrials. gov, NCT01495715. 2012.
41. Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012; 105: 91-102.
42. Blankenberg FG, Kinsman SL, Cohen BH, Goris ML, Spicer KM, Perlman SL, et al. Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease. Mol Genet Metab 2012; 107: 690-699.
43. Martinelli D, Catteruccia M, Piemonte F, Pastore A, Tozzi G, Dionisi-Vici C, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease-Genetically defined Leigh Syndrome. Mol Genet Metab 2012; 107: 383-388.
44. Finsterer J. Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol 2008; 39: 223-235.
45. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20: 1502-1509.
46. Klopstock T, Querner V, Schmidt F, Gekeler F, Walter M, Hartard M, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000; 55: 1748-1751.
47. Kornblum C, Schroder R, Muller K, Vorgerd M, Eggers J, Bogdanow M, et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur J Neurol 2005; 12: 300-309.
48. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35: 235-242.
49. Taivassalo T, Shoubridge EA, Chen J, Kennaway NG, DiMauro S, Arnold DL, et al. Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol 2001; 50: 133-141.
50. Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain 2003; 126: 413-423.
51. Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ, et al. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain 2006; 129: 3391-3401.
52. Haller RG. The effects of exercise vs. inactivity on people with mitochondrial muscle diseases; ClinicalTrials. gov; NCT00457314. 2012.
53. DeBrosse S, Okajima K, Zhang S, Nakouzi G, Schmotzer C, Lusk-Kopp M, et al. Spectrum of neurological and survival outcomes in pyruvate dehydrogenase complex (PDC) deficiency: Lack of correlation with genotype. Mol Genet Metab 2012; 107: 394-402.
54. Murphy JL, Blakely EL, Schaefer AM, He L, Wyrick P, Haller RG, et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008; 131: 2832-2840.